SureTrader SPDR Advertisement SPDR Advertisement
Home > Boards > US OTC > Cannabis >

Cannabis Science, Inc. (CBIS)

CBIS RSS Feed
Add CBIS Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator mick, newmedman, mckinley1, Homebrew
Search This Board:
Last Post: 7/30/2015 9:21:18 PM - Followers: 1048 - Board type: Free - Posts Today: 0

CannabisScience.com

Contact Us
Cannabis Science, Inc.
6946 North Academy Boulevard
Suite B #254
Colorado Springs, CO 80918
Email: info@cannabisscience.com
Tel: +1 (888) 777-0658
Fax: +1 (866) 943-5085

INVESTOR INQUIRIES
Robert Kane - CFO & Director
Email: robert.kane@cannabisscience.com
Tel: +1 (561) 420-4824

 

                                         The Science of Cannabinoids

Recent advances in science have opened the door to develop, produce, and commercialize, a variety of effective whole plant cannabinoid based pharmaceutical products with a wide variety of important applications.
Although cannabis has been used medicinally for thousands of years, until very recently little was known about how it actually worked. Some uses of cannabis are well known, such as alleviating nausea and stimulating the appetite for people with AIDS and cancer.

Other well-known uses include chronic pain, and reducing muscle spasms associated with neuromuscular disorders like MS and spinal cord injuries. Some current uses are poorly understood, such as its effectiveness in alleviating certain autoimmune disorders such a Crohn's Disease.

 

Our Market


The mainstream pharmaceutical industry is capital-intensive and constrained by high regulatory hurdles, making the profitability of any particular product a long-term prospect. Cannabis Science™ is different in three key respects:
The Company will, at least in its first phase of existence, deal primarily in intellectual properties "patents on products and processes" leaving capital-intensive problems such as regulatory compliance, mass production and marketing to the "old guard" pharmaceutical companies who license our patents.
We will focus on a relatively new and under-explored niche in the pharmaceutical market: Whole-plant cannabinoid compounds derived from certified organic ingredients. The existing pharmaceutical industry is heavily geared, by inclination and in terms of infrastructure, toward the development and testing of synthetic compounds.
Cannabis Science™ has strong roots in, and an established relationship of trust with, the US and Canadian medical cannabis patient communities. In the course of product and process development, we'll do "well" by doing "good" - our products will receive baseline efficacy testing in that community. Since medical cannabis already inherently exceeds all reasonable standards of safety, potential licensees will approach the regulatory process with a reasonable expectation that the products and processes they license will easily exceed that process's safety and efficacy standards. Thus our products and processes will enjoy a significant advantage over previously untested synthetics.

 

Board Of Directors

Dr. Robert J. Melamede, Ph.D.  - President & Director
Dr. Melamede has a Ph.D. in Molecular Biology and Biochemistry from the City University of New York. He retired as Chairman of the Biology Department at University of Colorado, Colorado Springs in 2005, where he continues to teach. Dr. Melamede is recognized as a leading authority on the therapeutic uses of cannabis, and has authored or co-authored dozens of papers on a wide variety of scientific subjects. Dr. Melamede also serves on the Advisory Board of The Journal of the International Association for Cannabis as Medicine, and the Scientific Advisory Board Medical of the Marijuana Policy Advocacy Project, as well as the Scientific Advisory Board of Americans for Safe Access. He also served as a director of Newellink Inc, a Colorado-based company specializing in cancer research.

Dr. Dorothy Bray, Ph.D. - Chief Executive Officer and Director
Dr. Dorothy Bray, Ph.D., Former Global Director of HIV Research and Senior Clinical Program Head of HIV and Opportunistic Infections for GlaxoSmithKline. Dr. Bray held various positions of responsibility at GlaxoSmithKline.

Dr. Bray is the President and owner of ImmunoClin as well as a member of the Scientific Staff and the Head of Scientific Business Development of The Medical Research Council Clinical Trials Unit. As well, Dr. Bray has authored or co-authored multiple publications and has an extensive network of collaborations and contacts with pharmaceutical companies, governments, and non- government organizations in key developed and developing markets; European Commission Scientific Expert.
Robert Kane - Chief Financial Officer and Director
Mr. Kane wrote his first business plan in 1996. In 1998, he was hired at Ryan, Beck, and Company, which was bought by the 120-year-old, top ten, financial firm Stifel Nicolaus (NYSE: SF) as a registered representative.  
On December 31,
2009, Mr. Kane walked away from the financial markets and started his own firm, Robert Kane Partners, which specializes in business and management planning, investor presentations, and investor relations.  
Mr. Kane held the position of Director of Investor Relations for Medical Marijuana, Inc., the first ever publicly traded medical marijuana company. He also held the position of Chief Financial Officer for “Cannabiz Business University.”  Robert Kane's mission is transforming and leading the Medical Cannabis Industry into a viable investment alternative for all types of investors.
 

 


Dr. Roscoe M. Moore, Jr., D.V.M., Ph.D., D.Sc.
Until his retirement, Dr. Roscoe M. Moore, Jr. served with the United States Department of Health and Human Services (HHS) and was for the last twelve years of his career the principal person responsible for global development support within the Office of the Secretary, HHS, with primary emphasis on Continental Africa and other less developed countries of the world. He was the principal liaison person between the HHS and Ministries of Health in Africa with regard to the development of infrastructure and technical support for the delivery of preventive and curative health needs for the continent.Dr. Moore received his Bachelor of Science and Doctor of Veterinary Medicine degrees from Tuskegee Institute; his Master of Public Health degree in Epidemiology from the University of Michigan; and his Doctor of Philosophy degree in Epidemiology from the Johns Hopkins University. He was awarded the Doctor of Science degree (Honoris Causa) in recognition of his distinguished public health career by Tuskegee University.
Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service (USPHS) entering with the U.S. National Institutes of Health (NIH) and rising to the rank of Assistant United States Surgeon General (Rear Admiral, USPHS) within the Immediate Office of the Secretary, HHS. He was selected as Chief Veterinary Medical Officer, USPHS, by Surgeon General C. Everett Koop.
Dr. Moore served as an Epidemic Intelligence Service Officer with the U.S. Centers for Disease Control and Prevention (CDC). He was with the Center for Veterinary Medicine, U.S. Food and Drug Administration (FDA), before becoming Senior Epidemiologist within the National Institute for Occupational Safety and Health, CDC. He served as the Chief Epidemiologist with the Center for Devices and Radiological Health, FDA. He directed the Epidemiology and Biostatistics Program and was an Assistant Professor of Oncology within the Howard University College of Medicine Cancer Center.

Dr. Dorothy Bray, Ph.D.
Dr. Dorothy Bray, Ph.D., Former Global Director of HIV Research and Senior Clinical Program Head of HIV and Opportunistic Infections for GlaxoSmithKline, to the Company’s Scientific Advisory Board. Dr. Bray held various positions of responsibility at GlaxoSmithKline.
Dr. Bray is the President and owner of ImmunoClin as well as a member of the Scientific Staff and the Head of Scientific Business Development of The Medical Research Council Clinical Trials Unit. As well, Dr. Bray has authored or co-authored multiple publications and has an extensive network of collaborations and contacts with pharmaceutical companies, governments, and non- government organizations in key developed and developing markets; European Commission Scientific Expert.
Dr. Bray’s extensive experience in the field of HIV drug development will compliment Cannabis Sciences’ prestigious Scientific Advisory Board as the company embarks on the research and development of a phytocannabinoid based HIV TAT inhibitor. Dr. Bray has significant expertise in clinical development and market positioning for novel drugs.

 

Policy Advisory Board

Robert Raich Esq
Robert A. Raich practices law in Oakland, California, and is a graduate of Harvard University and the University of Texas School of Law. He is one of the most respected attorneys in the area of medical marijuana. He is General Counsel of the Oakland Cannabis Buyers' Cooperative, and was one of the attorneys in the U.S. Supreme Court case, United States v. Oakland Cannabis Buyers' Coop. and another federal medical cannabis case. He is a member of the California Attorney General's Medical Marijuana Task Force (Chairman, Caregiver Issues Subcommittee).

Sean T. McAllister Esq
Sean T. McAllister is public interest attorney with offices in Denver and Summit County. Sean has been involved with drug policy reform efforts for over a decade. Sean serves as the Chair of the Board of Directors of Sensible Colorado. Sean is a lifetime member of the NORML Legal Committee. He is a member and Board member of the Colorado Criminal Defense Bar. He helped start the Colorado Bar Association Criminal Sentencing Project in 2005 to focus on criminal justice and drug policy reform. Recently, Sean was appointed to the Governor's Drug Policy Task Force, which is working on reducing drug-sentencing laws to save the state money while maintaining public safety. Along with Brian Vicente, Sean recently founded the Canna-Business Institute designed to educate dispensary owners and caregivers on how to legally operate medical marijuana businesses in Colorado.

Warren Edson Esq
Warren Edson is an experienced criminal defense lawyer in Colorado having taken part in over 1,000 trials. He is also one of the organizers of Colorado's Medical Marijuana Law, Amendment 20, and is a Lifetime Member, NORML Legal Committee, and is a member, Colorado Criminal Defense Bar, and the National Association of Criminal Defense Lawyers, and is a Board Member, Colorado NORML.

Robert J. Corry, Jr. Esq
Robert J. Corry, Jr. is a Denver-based civil rights and criminal defense attorney, specializing in medical marijuana, who has successfully litigated several high profile cases around the country. He is admitted to the bars of Colorado, California, and Washington, D.C., federal courts in these jurisdictions, as well as the U.S. Supreme Court. Mr. Corry earned his law degree from Stanford University.

Brian Vicente, Esq
Brian Vicente, Esq., a Denver defense attorney who serves as executive director of Sensible Colorado, the states leading non-profit working for medical marijuana patients and caregivers. He is also the chairman of the Denver Mayor's Marijuana Policy Review Panel and coordinates the Colorado Bar Association's Drug Policy Project. He was awarded the prestigious Gideon award for his free speech advocacy during the 2008 Democratic National Convention.

 

Products Overview

Our products, broadly described, is medical cannabis - a term which encompasses a wide variety of products, ranging from plants grown by patients for their own use to pharmaceutical products developed from one or more of the cannabinoid compounds found in the whole cannabis plant.

Cannabinoids are a group of terpenophenolic compounds present in Cannabis (Cannabis sativa L). Currently, 538 natural compounds were identified from this plant.  43 of these 108 are identified as cannabinoids, which are C21 compounds uniquely present in Cannabis sativa L. There are ten main types of cannabinoids and fourteen different cannabinoid subtypes. Tetrahydrocannabinol (THC) is the principal psychoactive ingredient in cannabis, but it also has other effects. Cannabidiol (CBD) and cannabinol (CBN) are the other two most prevalent natural cannabinoids and have received the most study. All three are listed as ingredients in Sativex®, the only multi-cannabinoid medicine currently approved for marketing (only in Canada.)

Cannabinoids were first discovered in the 1940s, when CBD and CBN were identified. THC was not identified until 1964, but by that time cannabis had been removed from the pharmacopeiae of most countries, making further research on the plant difficult.

There are three general types of cannabinoids:
1) Phytocannabinoids that occur uniquely in the cannabis plant.
2) Endogenous cannabinoids produced naturally in many animal species including humans.
3) Synthetic cannabinoids are similar compounds produced in a laboratory. Forms of synthetic THC are available by prescription in a number of countries, including the US. In the US, synthetic THC is marketed as Marinol®.
Phytocannabinoids, also called natural cannabinoids, herbal cannabinoids, and classical cannabinoids, are only known to occur naturally in significant quantity in the cannabis plant. They are concentrated in a viscous resin that is produced in glandular structures known as trichomes, and are most prevalent in the flowers of the female plants.
Cannabinoid receptors in the human body were not discovered until 1990. CB1 receptors are found primarily in the brain, specifically in the basal ganglia and in the limbic system, including the hippocampus. They are also found in the cerebellum and in both male and female reproductive systems.
CB1 receptors appear to be responsible for the euphoric and anti-convulsive effects of cannabis.

 

Investors Overview

Cannabis Science Inc.
Trading Symbol: CBIS

Transfer Agent 
Securities Transfer Corporation 
2591 Dallas Parkway 
Suite 102 
Frisco, Texas 75034 
Telephone: (469) 633-0101 ext. 201 
Fax: (469) 633-0088 
Website: www.stctransfer.com

AUTHORIZED SHARES
Common Class B
850,000,000
  Common Class A
100,000,000
Preferred
1,000,000

SHARES OUTSTANDING
Common, Class B
29,744,774 a/o Dec 32, 2009
101,170,574 a/o Dec 31, 2010
305,820,574 a/o Dec 31, 2011
602,170,573 a/o May 21, 2012 
691,770,573 a/o Aug 13, 2012
699,290,000 a/o Nov 8, 2012
714,540,573 a/o Nov 19, 2012
704,290,573 a/o Dec 17, 2012
823,523,000 a/o Mar 13, 2014
Common, Class A
0
Preferred
1,000,000

Stock Chart



Proposed Dividend / Share Structure

 

New Share Structure
On December 20, 2010, our Board of Directors approved an amendment to the Articles of Incorporation to effect a recapitalization of the Company by establishing two classes of common stock, Class A and Class B and to issue a dividend to holders of our current common stock so they received 1 share of the new Class A common stock and 1 non-transferable share purchase warrant for each 10 shares of the former Class B common stock that they previously owned as of the current record date, December 31, 2010. Each whole share purchase warrant will be exercisable into one share of Class A common stock at a price of $1.00 per share. The share purchase warrants expire 90-days from the date Class A common stock commences trading under its own unique symbol. The Company is working diligently with the SEC and FINRA to obtain final approvals before any of the proposed changes can take effect.


DEF 14C Filed to give Dividend and Create New Share Class

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8108378

* Dividend will go to shareholders as of Dec 31, 2010
* Shareholders will receive 1 share of Class A stock (the new ticker) for every 10 shares of the current stock
* Shareholders will receive 1 purchase warrant for every 10 shares of the current stock. The warrants can be used to purchase Class A stock at $1 for 90 days.

 
Dividends (April 23, 2013)-10-K
 
The Company declared a dividend to all common stockholders of record as of December 31, 2010, whom are to receive a dividend equivalent to ten percent (10%) of the number of common shares of the Company's stock held on that date in the form of newly issued Series A common shares. For example, if a stockholder held 100,000 common shares on December 31, 2010, that stockholder would receive a dividend of 10,000 Series A common shares. This dividend is on hold and will remain pending until such time as FINRA approves the Company's Series A common stock for trading, it obtains a CUSIP registration number, it receives sponsorship from a brokerage firm, and the shares become tradable through the OTCBB market. TheCompany retains the right to adjust the shareholder record date should any factor make it impossible for the Company to issue the dividend to shareholders of record on December 31, 2010, including, but not limited to: approval of the Series A common stock and dividend by FINRA, a detailed December 31, 2010 common stockholder lists is available, or other unforeseen obstacles that would prevent the current dividend structure from completing. The Company will not make any share accrual or allowance for this dividend until such time as all regulatory approvals are in place for the Series A common stock to be issued and become a marketable security.
 
The Company does not anticipate paying cash dividends or making distributions in the foreseeable future.
 
We currently intend to retain and reinvest future earnings, if any, to finance and expand our operations.
 
We incurred a net loss of $86,574,241 since January 27, 2005 (date of inception) to December 31, 2012.
Our net loss increased, from $8,339,044 for the fiscal year ended December 31, 2011 to $16,037,572 at the fiscal year ended
December 31, 2012, an increase of $7,698,528. For the fiscal year ended December 31, 2012, our net loss per share was $0.03,
compared to a net loss per share of $0.05 per share for the fiscal year ended December 31, 2011.
The Company is authorized to issue 850,000,000 shares of common stock with a par value of $.001 per share. These shares
have full voting rights. There were 663,790,573 issued and outstanding as of December 31, 2012.
The Company is also authorized to issue 100,000,000 shares of common stock, Class A with a par value of $.001 per share.
These shares have 10 votes per share. There were 0 issued and outstanding as of December 31, 2012.
The Company is also authorized to issue 1,000,000 shares of preferred stock. These shares have full voting rights of 1,000
votes per share. On December 20, 2012 the former CFO of the Company, Richard Cowan, resigned and notified the Company
of his forfeiture of 333,333 series A preferred shares for return into treasury of the Company. There were 666,666 issued and
outstanding series A preferred shares as of December 31, 2012 as a result of this forfeiture.

On February 9, 2012, the Company established a 2012 Equity Compensation Plan that authorizes the Company to issue up to
50,000,000 common shares to staff or consultants for services to or on behalf of the Company. The Company filed a
Registration Statement Form S-8 with the U.S. Securities
 
Our management conducted an evaluation of the effectiveness of our internal control over financial reporting using the criteria
set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated
Framework at December 31, 2012. Based on its evaluation, our management concluded that, as of December 31, 2012, our
internal control over financial reporting was not effective because of limited staff and a need for a full-time chief financial
officer. A material weakness is a deficiency, or a combination of control deficiencies, in internal control over financial
reporting such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial
statements will not be prevented or detected on a timely basis.

 
====================================================
2014 Financial Highlights (from 10-K)


Net Loss $ 16,884,764  (2013:5,934,301)

Accumulated Deficit  $ 109,393,306 (2013: 92,508,542)

Revenue (educational and consulting)  $ 1,031

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10637231
 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CBIS
Current Price
Volume:
Bid Ask Day's Range
Wiki
CBIS News: Quarterly Report (10-q) 07/28/2015 01:01:54 PM
CBIS News: Current Report Filing (8-k) 06/30/2015 06:06:54 AM
CBIS News: Amended Statement of Changes in Beneficial Ownership (4/a) 06/18/2015 06:35:38 PM
CBIS News: Amended Statement of Changes in Beneficial Ownership (4/a) 06/18/2015 06:30:37 PM
CBIS News: Amended Statement of Changes in Beneficial Ownership (4/a) 06/18/2015 06:24:46 PM
PostSubject
#112944  Sticky Note Beware the CBIS SCAM!! Good DD here exposing Homebrew 05/01/15 09:10:13 PM
#112499  Sticky Note Cannabis Science Set to Release its First Line oystersnbeer 03/09/15 09:29:48 AM
#111634  Sticky Note in full, Cannabis Science Releases Positive Laboratory Results mick 10/28/14 11:10:48 AM
#113311   Thanks, I will do much more DD here. Peacefulwendy 07/30/15 09:21:18 PM
#113310   Dig into his product release scams just since sicofbs 07/30/15 08:53:05 PM
#113309   Might want to google sicofbs 07/30/15 06:05:49 PM
#113308   That would be Mario Lap he is...... LongShot_Louie 07/30/15 04:52:24 PM
#113307   Wow! That's not a good sign... LMAO Peacefulwendy 07/30/15 04:49:37 PM
#113306   He is the dude who ran the cbis sicofbs 07/30/15 04:12:11 PM
#113305   Thanks Louie. I think I will put them Peacefulwendy 07/30/15 03:53:30 PM
#113304   They purport to have four legs...... LongShot_Louie 07/30/15 03:22:03 PM
#113303   I owned this one a few years ago Peacefulwendy 07/30/15 01:51:47 PM
#113302   Sub penny coming up!!! or should I say Mediman420 07/29/15 03:49:47 PM
#113301   The new rookies on their roster.... LongShot_Louie 07/29/15 01:37:40 PM
#113300   This thing is still trading? DAWD. Doc K 07/29/15 12:46:05 PM
#113299   It it too late as there are news Doc K 07/29/15 12:44:25 PM
#113298   Cannabis Science Signs Gary Blick, MD and Proceeds LongShot_Louie 07/29/15 12:11:46 PM
#113297   Are they still in final negotiations for that Doc K 07/28/15 11:17:45 PM
#113296   I could sit here and go through the Alan Brochstein 07/28/15 10:22:46 PM
#113295   0 revenue and trading this high?!.... Liquid1974 07/28/15 05:01:47 PM
#113294   http://investorshub.advfn.com/boards/getboards.aspx?searchstr=CBIS mick 07/28/15 12:06:40 PM
#113293   What .... No fire extinguishers... Nothing .... Banner sicofbs 07/27/15 04:03:24 PM
#113292   Did the cows come home ?? Can Homebrew 07/26/15 12:09:04 AM
#113291   Hey Kane!!! newmedman 07/25/15 01:42:50 PM
#113288   Just another dabney product scam played out again sicofbs 07/24/15 05:22:52 PM
#113287   Besides the fact that cbis has claimed product sicofbs 07/24/15 12:59:26 PM
#113286   Ok...,you believed dabney...lol...this like the December 5 th sicofbs 07/24/15 12:37:18 PM
#113285   Well, it is July 23rd and I guess LongShot_Louie 07/24/15 07:46:42 AM
#113284   Product ? sicofbs 07/24/15 07:38:03 AM
#113283   divy? sundoctor 07/23/15 08:17:17 PM
#113282  Restored I hate that part about war.... newmedman 07/23/15 07:20:21 PM
#113281   Nobody said it would be a cake walk..... LongShot_Louie 07/23/15 04:17:05 PM
#113280   Must have been an impressive presentation at the newmedman 07/23/15 12:51:46 PM
#113279   Mark Wainberg, Ph.D., Joins Cannabis Science's Scientific Advisory LongShot_Louie 07/23/15 11:03:58 AM
#113278   Does anyone else think dabney Kane and Johnson sicofbs 07/23/15 10:25:16 AM
#113277   "This week" right Dabney....lol.... sicofbs 07/23/15 07:59:51 AM
#113276   Dilution insymbols 07/22/15 01:07:09 PM
#113275   The dabney Kane bray and Johnson product release sicofbs 07/21/15 11:04:39 AM
#113274   Investors are not believing there will be a sicofbs 07/21/15 10:25:27 AM
#113273   CBIS lookin $trong Today along with HEM* ERB* KING_STOCK 07/20/15 09:59:26 AM
#113272   It looks like the last dozen or so sicofbs 07/19/15 11:20:03 PM
#113271   Starting to look interesting again. I know it's ShakeNTake 07/19/15 04:14:42 PM
#113270   OH boy...dabney expect to...plans to....same as he has sicofbs 07/19/15 09:13:38 AM
#113269   Cannabis Science, Inc. Initiates the Scientific Validation of LongShot_Louie 07/18/15 11:27:31 AM
#113268   It feels like the sun may be rising, U ROCK 07/18/15 09:37:12 AM
#113267   WE shall see next week exactly what they sicofbs 07/17/15 07:33:29 PM
#113266   SCAM SCAM SPAM rifreede 07/17/15 05:37:15 PM
#113265   When CBIS travels through a wormhole and enters Homebrew 07/17/15 03:25:01 PM
#113264   Divy.....I'm hoping to see the banner In the sicofbs 07/16/15 10:36:07 PM
#113263   when issue divy? sundoctor 07/16/15 10:02:58 PM
#113262   Sold GWP$ • Going BIG CBIS $ Stockadamus 07/16/15 01:12:28 PM
#113261   I could go on and in..but here is sicofbs 07/16/15 12:09:12 PM
#113260   Endocan Moves Forward With New Product Releases After sicofbs 07/16/15 12:04:26 PM
PostSubject